GlassScriptPhysician profile
Logan Price
NPI 1619717147
$1,113.95
in general payments reported to CMS, 2019-2025
20 companies · $981 in 2025
The $981 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $133 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Education: $57.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.94 |
| Education | $57.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.07 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $152.33 | 2024-2025 | Rexulti, Jynarque |
| Abbvie INC. | $141.66 | 2025 | |
| Axsome Therapeutics, INC. | $129.59 | 2025 | Auvelity |
| Lilly USA, LLC | $61.04 | 2025 | Jardiance, Mounjaro, Zepbound |
| Opko Pharmaceuticals, LLC | $57.01 | 2025 | Rayaldee |
| Novo Nordisk INC | $50.15 | 2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $44.35 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.32 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $39.85 | 2024-2025 | Verquvo |
| Lundbeck LLC | $39.02 | 2025 | Rexulti |
| Csl Behring | $33.01 | 2025 | Andembry |
| Travere Therapeutics, INC. | $30.60 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $25.64 | 2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $24.00 | 2024 | Spravato |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $19.11 | 2025 | Hetlioz, Fanapt |
| Dexcom, INC. | $18.43 | 2025 | Dexcom G6 Transmitter |
| Verona Pharma, INC. | $17.36 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $15.58 | 2025 | |
| Calliditas Therapeutics US INC. | $14.83 | 2025 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.